Bronchodilator Drugs - GCC | Statista Market Forecast

In the GCC market, revenue in the Bronchodilator Drugs market is forecasted to achieve a significant milestone, reaching a staggering figure of US$264.20m by the year 2024.
Furthermore, it is anticipated that this market will display a steady growth rate of 3.75% (CAGR 2024-2029), ultimately leading to a substantial market volume of US$317.60m by 2029.
When examining the global landscape, it is worth noting that United States is expected to generate the highest revenue, amounting to an impressive US$17.34bn in 2024.
The demand for bronchodilator drugs is rising in the GCC region due to the high prevalence of respiratory diseases.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The GCC region has witnessed a significant growth in the use of bronchodilator drugs in recent years.

Customer preferences: The increasing prevalence of respiratory diseases in the GCC region is the primary driver of the bronchodilator drugs market. The high prevalence of smoking, air pollution, and dust in the region has contributed to the rise in respiratory diseases. The growing awareness among people about the benefits of early diagnosis and treatment of respiratory diseases has also led to an increase in the demand for bronchodilator drugs.

Trends in the market: The bronchodilator drugs market in the GCC region is witnessing a shift towards combination therapies. Combination therapies are becoming increasingly popular as they offer a more effective treatment option for patients with severe respiratory diseases. The market is also witnessing a trend towards the use of long-acting bronchodilators, which provide a sustained bronchodilator effect and reduce the frequency of medication.

Local special circumstances: The GCC region has a high prevalence of smoking, which is a major risk factor for respiratory diseases. The governments in the region have implemented several initiatives to reduce smoking, such as increasing taxes on tobacco products and implementing anti-smoking campaigns. These initiatives are expected to reduce the prevalence of smoking in the region and, in turn, reduce the incidence of respiratory diseases.

Underlying macroeconomic factors: The GCC region has a high per capita income, which has contributed to the growth of the healthcare sector in the region. The governments in the region have invested heavily in the healthcare sector, which has led to the development of advanced healthcare infrastructure and the availability of high-quality medical services. The growing healthcare infrastructure and availability of medical services have contributed to the growth of the bronchodilator drugs market in the region.In conclusion, the bronchodilator drugs market in the GCC region is witnessing significant growth due to the increasing prevalence of respiratory diseases, the shift towards combination therapies, and the use of long-acting bronchodilators. The local special circumstances such as the high prevalence of smoking and the government initiatives to reduce smoking have also contributed to the growth of the market. The underlying macroeconomic factors such as the high per capita income and the growing healthcare infrastructure have further fueled the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.